Bernard L. Silverman, MD - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(16)

MIXED(1)

Medisorb naltrexone 380 mg

VIVITROL 380 mg

TrIP-2SS + Foradil

Medisorb naltrexone 190 mg

Oral naltrexone to Medisorb naltrexone 380 mg

+7 more interventions

15 unique interventions2 categories

Analytics

Trial Phases

Phase 11

Phase 24

Phase 34

Trial Status

Completed8

Terminated1

Role Distribution

Other Roles9

Activity Timeline

Clinical Trials (9)

NCT00156923Phase 3Completed

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism

Studydirector

NCT00156936Phase 3Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

AlcoholismOpiate Dependence

Studydirector

NCT00501631Phase 3Completed

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Alcohol Dependence

Studydirector

NCT00801684Phase 2Completed

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Chronic Obstructive Pulmonary Disease (COPD)

Studydirector

NCT01100151Phase 2Completed

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

Opioid-induced Constipation

Studydirector

NCT01218984Phase 2Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence

Studydirector

NCT01218997Phase 3Completed

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism

Studydirector

NCT01366001Phase 1Completed

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

Cocaine Abuse

Studydirector

NCT01903837Phase 2Completed

A Study of ALKS 3831 in Adults With Schizophrenia

Schizophrenia

Studydirector

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Alcoholism4 Opioid-Related Disorders2 Pulmonary Disease, Chronic Obstructive1 Cocaine Abuse1 Opioid-Induced Constipation1 Schizophrenia1

Affiliations

Alkermes, Inc.

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Robert B Innis, M.D.

National Institute of Mental Health (NIMH)

Shared therapeutic areas:

AlcoholismSchizophrenia

Similarity Score10%

Konrad E Bloch, MD

University Hospital, Zürich

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

loic MONDOLONI

Assistance Publique Hopitaux De Marseille

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Talant M Sooronbaev, MD

National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Mitesh Patel, MD, MBA, MS

University of Pennsylvania

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Jean-Olivier ARNAUD, Director

Assistance Publique Hôpitaux de Marseille

Shared therapeutic areas:

Similarity Score5%

Suman Sheraz, PhD*

Riphah International University

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Glen P Kenny, PhD

University of Ottawa

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Christelle Haziza, PhD

Philip Morris Products S.A.

Shared therapeutic areas:

Pulmonary Disease, Chronic Obstructive

Similarity Score5%

Urielle Desalbres

Assistance Publique Hôpitaux de Marseille

Shared therapeutic areas:

Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (9)

Showing 9 of 9 trials

NCT00156923Phase 3StudyDirector

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism

Completed

NCT00156936Phase 3StudyDirector

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

AlcoholismOpiate Dependence

Terminated

NCT00501631Phase 3StudyDirector

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Alcohol Dependence

Completed

NCT00801684Phase 2StudyDirector

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Chronic Obstructive Pulmonary Disease (COPD)

Completed

NCT01100151Phase 2StudyDirector

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

Opioid-induced Constipation

Completed

NCT01218984Phase 2StudyDirector

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence

Completed

NCT01218997Phase 3StudyDirector

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism

Completed

NCT01366001Phase 1StudyDirector

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

Cocaine Abuse

Completed

NCT01903837Phase 2StudyDirector

A Study of ALKS 3831 in Adults With Schizophrenia

Schizophrenia

Completed

All 9 trials loaded